يعرض 61 - 80 نتائج من 12,925 نتيجة بحث عن '(((( 50 ((mean decrease) OR (we decrease)) ) OR ( 50 c decrease ))) OR ( 50 ng decrease ))', وقت الاستعلام: 0.59s تنقيح النتائج
  1. 61
  2. 62
  3. 63
  4. 64
  5. 65

    Presentation_1_Airway macrophages display decreased expression of receptors mediating and regulating scavenging in early cystic fibrosis lung disease.pdf حسب Lisa J. M. Slimmen (16464600)

    منشور في 2023
    "…AM expression of immune checkpoint molecule SIRPα also decreased with age (p = 0.0006), but did not correlate with BALF %neutrophils. …"
  6. 66
  7. 67
  8. 68

    Experimental protocol. حسب Hiroyuki Matsuta (13250169)

    منشور في 2022
    الموضوعات:
  9. 69
  10. 70

    Fig 3 - حسب Hiroyuki Matsuta (13250169)

    منشور في 2022
    الموضوعات:
  11. 71
  12. 72
  13. 73
  14. 74
  15. 75

    Diabetic kidney shows decreased klotho expression. حسب Jeong Suk Kang (7359572)

    منشور في 2021
    "…<p>(a) Representative images of the kidney from normal and diabetic biopsies showing the decreased klotho expression in diabetic podocytes by IHC. …"
  16. 76
  17. 77
  18. 78
  19. 79

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation حسب Kairui Yue (11874403)

    منشور في 2022
    "…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …"
  20. 80

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation حسب Kairui Yue (11874403)

    منشور في 2022
    "…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …"